Therefore, APOE–POLG interaction not only influences the age of diagnosis of PD but also impacts cerebrospinal fluid (CSF) biomarkers, offering potential avenues for early diagnosis and targeted therapies. The gene discussed is APOE; the disease is Parkinson disease.